Key Developments For Chindex International, Inc.
Chindex International, Inc. (CHDX.O) (Consolidated Issue listed on NASDAQ Global Market)
Chindex International, Inc. Announces New CDC Contract
Chindex International, Inc. announced that it has entered into a contract to supply EUR5 million in laboratory and hospital products to Centers for Disease Control in China'sQinghai Province. The purchase is being financed by the KfW Development Bank of Germany under a government to government program. The signing ceremony was held in Beijing and the contract is expected to ship during the current fiscal year.
Chindex International, Inc. Announces Exclusive Distribution Agreements In China For Clinical Chemistry And Aesthetic Laser Products
Chindex International, Inc. announced that it has entered into two new exclusive, multi-year distribution agreements for China with Biotest AG and Cutera Inc. Biotest AG, based in Dreieich, Germany, specializes in innovative hematology and immunology products. Biotest has appointed Chindex as the exclusive distributor for its unique Tango Optimo Automated Blood Bank System for the People's Republic of China. The Tango Optimo automates all routine testing procedures performed in blood banking, including blood grouping, antibody screening, and cross matching, and is the only blood bank analyzer that offers seven-day on-board storage of liquid and microplate reagents. Upon receipt of regulatory approval from China's State Food and Drug Administration, Chindex will market the Tango Optimo to hospital laboratories along with the Johnson & Johnson Ortho Clinical Diagnostics line of clinical chemistry analyzers.
ACM Global Central Lab Announces Partnership With Chindex International, Inc.'s United Family Hospitals In China
Chindex International, Inc. and ACM Global Central Laboratory announced a partnership to provide central lab services in China at United Family Hospitals, Beijing (UFH). UFH is a CAP certified facility owned by Chindex International, Inc.
Chindex International, Inc. Issues Q2 2009 Guidance Below Analysts' Estimates; Raises H2 2009 Revenue Guidance; Issues FY 2009 Revenue Guidance In Line With Analysts' Estimates
Chindex International, Inc. announced that for second quarter 2009 it expects to report revenue of $38.1 million and net income of $862,000, or $0.05 per diluted share. The Company increased its revenue outlook for the second half of 2009 and expects fiscal 2009 revenue in the range of $160-$170 million. According to Reuters Estimates, analysts are expecting the Company to report revenue of $39.9 million and EPS of $0.15 for second quarter 2009; revenue of $160 million for fiscal 2009.
Chindex International, Inc. Announces Second daVinci Sale
Chindex International, Inc. announced that its Medical Products division has been awarded another major contract. The Company has signed its second contract for the sale of a new daVinci S system in mainland China, demonstrating strong interest and demand for this cutting-edge, minimally-invasive surgical technology.
